MSCLF News and Press, Satellos Bioscience Inc. From 08/13/25

Reported positive Phase 1b data in five adults with Duchenne muscular dystrophy (DMD) after 28 days of treatment Demonstrated safety, tolerability and an approximate doubling in grip strength On track to initiate a follow-up of the Phase 1b study in adults with DMD in ...

Xenon Pharmaceuticals Inc. (XENE) is expected to report $-1.03 for Q2 2025 Gaia Inc. (GAIA) is expected to report $-0.08 for Q2 2025 Insight Molecular Diagnostics Inc. (IMDX) is expected to report for Q2 2025 Lightbridge Corporation (LTBR) is expected to report for Q2 2025 NewHold...

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company” ), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present at the Canaccord Genuity’s 45th Annual Gro...

2025-07-16 07:34:31 ET Read the full article on Seeking Alpha For further details see: Satellos Bioscience names new chief medical officer

Brings a successful track record in clinical development and regulatory approval of innovative neuromuscular therapies Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a biotech company developing new...

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced the election of Iris ...

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced its participation in ...

Phase 1b data shows treatment with SAT-3247 was safe and well-tolerated Pharmacokinetic (PK) profile of SAT-3247 translated as expected to Duchenne Muscular Dystrophy (DMD) patients taking concurrent steroids Potential trend to improved grip strength observed, with average strengt...

2025-05-13 14:08:15 ET More on Satellos Bioscience Historical earnings data for Satellos Bioscience Financial information for Satellos Bioscience Read the full article on Seeking Alpha For further details see: Satellos Bioscience GAAP EPS of -$0.04

urban-gro Inc. (UGRO) is expected to report for quarter end 2025-03-31 Karman Holdings Inc. (KRMN) is expected to report $0.02 for Q1 2025 PyroGenesis Inc Com (PYRGF) is expected to report for quarter end 2025-03-31 GeoVax Labs Inc. (GOVX) is expected to report $-0.59 for Q1 2025 ...